Last $52.66 USD
Change Today +0.72 / 1.39%
Volume 175.2K
ICLR On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

icon plc (ICLR) Snapshot

Open
$51.81
Previous Close
$51.94
Day High
$52.99
Day Low
$51.65
52 Week High
10/22/14 - $59.81
52 Week Low
04/30/14 - $35.33
Market Cap
3.2B
Average Volume 10 Days
373.6K
EPS TTM
$2.60
Shares Outstanding
61.6M
EX-Date
--
P/E TM
20.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for ICON PLC (ICLR)

icon plc (ICLR) Related Businessweek News

No Related Businessweek News Found

icon plc (ICLR) Details

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, Rest of Europe, the United States, and internationally. It specializes in the development, management, and analysis of programs that support various stages of the clinical development process-from compound selection to Phase I-IV clinical studies. The company also offers clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics, and laboratory services. Its clinical research services include investigator recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety monitoring, clinical data management, interactive voice response technologies, electronic patient reported outcomes, medical reporting, patient registries, outcomes research, health economics, and marker access and commercialization services. The company’s clinical research services also comprise strategic analysis and data operation, clinical pharmacology, bioanalysis, immunoassay development, pharmacokinetic and pharmacodynamic analysis, study protocol preparation, regulatory consulting, product development planning, strategic consulting, pricing and market access consulting, medical imaging, contract staffing, and electronic endpoint adjudication, sample analyses, safety testing, microbiology, custom flow cytometry, electronic transmission of test results, and biomarker development services. ICON Public Limited Company was founded in 1990 and is headquartered in Dublin, Ireland.

10,700 Employees
Last Reported Date: 10/29/14
Founded in 1990

icon plc (ICLR) Top Compensated Officers

Chief Executive Officer, Director and Chairma...
Total Annual Compensation: €1.8M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €664.0K
Chief Operating Officer
Total Annual Compensation: €934.0K
Compensation as of Fiscal Year 2013.

icon plc (ICLR) Key Developments

Biomarkers Consortium of the Foundation for the National Institutes of Health and ICON plc Develop PRO Instrument for Hospital-Acquired Bacterial Pneumonia Trials

ICON plc has received a project from the FDA to develop an industry-standard patient reported outcome, or PRO, measure that can be used in antibacterial drug development trials for hospital-acquired bacterial pneumonia, or HABP. ICON's Commercialisation and Outcomes group, in collaboration with the Biomarkers Consortium of the Foundation for the National Institutes of Health (FNIH), aims to address an unmet need for a well-defined, reliable endpoint that can measure the effects of antibacterial drugs on HABP patients. The project involves creating a HABP PRO instrument with established content validity in accordance with the FDA Drug Development Tool qualification process. The new PRO would assess the symptoms of HABP at various time points over the course of the infection. The collaboration brings together scientists from ICON, the FDA, the National Institute of Allergy and Infectious Diseases, the Infectious Diseases Society of America, pharmaceutical and biotechnology companies, and the academic research community to develop new approaches to evaluating the efficacy of antibiotics in future clinical trials of therapies for HABP.

ICON Public Limited Company Announces Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2014 ; Increases Earnings Guidance for the Full Year 2014

ICON Public Limited Company announced unaudited consolidated earnings results for third quarter and nine months ended September 30, 2014. For the quarter, the company reported net revenue of $387,589 million, income from operations of $59,423 million, income before provision for income taxes of $59,532 million, net income of $50,316 million or $0.79 per diluted share compared to the net revenue of $339,810 million, income from operations of $33,161 million, income before provision for income taxes of $33,105 million, net income of $27,808 million or $0.45 per diluted share for the same quarter a year ago. For the nine months period, the company reported net revenue of $1,113,243 million, income from operations of $150,709 million, income before provision for income taxes of $150,871 million, net income of $127,294 million or $2.01 per diluted share compared to the net revenue of $990,818 million, income from operations of $91,489 million, income before provision for income taxes of $91,148 million, net income of $76,515 million or $1.23 per diluted share for the same period a year ago. The company guidance for the full year 2014 has been updated, with EPS guidance increased from a range of $2.62 - $2.68 to a range of $2.74 - $2.79 and revenue guidance, updated for fx, from a range of $1,490 million - $1,530 to a range of $1,495 million - $1,515 million.

SEC Orders Hearings On Registration Suspension Or Revocation Against Icon Public Ltd. Co. For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Icon Public Ltd. Co. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICLR:US $52.66 USD +0.72

ICLR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Charles River Laboratories International Inc $63.59 USD +0.33
Covance Inc $103.73 USD +0.02
INC Research Holdings Inc $26.13 USD +0.44
PAREXEL International Corp $56.48 USD +0.57
WuXi PharmaTech Cayman Inc $34.14 USD +0.44
View Industry Companies
 

Industry Analysis

ICLR

Industry Average

Valuation ICLR Industry Range
Price/Earnings 20.8x
Price/Sales 2.2x
Price/Book 3.2x
Price/Cash Flow 15.4x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICON PLC, please visit www.iconplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.